DSC
MACK

Duncker Streett & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Duncker Streett & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-38
Closed -$3K – 620
2016
Q1 		$3K Hold
38
– – ﹤0.01% 579
2015
Q4 		$2K Hold
38
– – ﹤0.01% 618
2015
Q3 		$3K Hold
38
– – ﹤0.01% 598
2015
Q2 		$4K Hold
38
– – ﹤0.01% 590
2015
Q1 		$4K Hold
38
– – ﹤0.01% 593
2014
Q4 		$3K Hold
38
– – ﹤0.01% 602
2014
Q3 		$3K Buy
+38
New +$2.03K ﹤0.01% 612

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Duncker Streett & Co's MACK Position: Q2 2016 in Review

Duncker Streett & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2016, closing a stake of 38 shares — an estimated $3K sold.

Duncker Streett & Co first reported a position in MACK in Q3 2014 and held it in 7 quarters. The position peaked at $4K in Q2 2015. 140 funds tracked by Wall St. Rank hold MACK as of Q2 2016.

  • Duncker Streett & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Duncker Streett & Co sold 38 Merrimack Pharmaceuticals, Inc. shares in Q2 2016, an estimated $3K.
  • Duncker Streett & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 7 quarters.
  • Duncker Streett & Co's Merrimack Pharmaceuticals, Inc. position peaked at $4K in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2016.

Based on Duncker Streett & Co's 13F filing for Q2 2016, filed 20 Jul 2016.